$1.70
-0.34 (-16.67%)
Open$2.20
Previous Close$2.04
Day High$2.20
Day Low$1.57
52W High$13.96
52W Low$0.14
Volume—
Avg Volume296.5K
Market Cap1.54M
P/E Ratio—
EPS$-13.92
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+880.6% upside
Current
$1.70
$1.70
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.36M | 586.6K | 551.3K |
| Net Income | -218,664,187 | -23,280 | -22,798 |
| Profit Margin | -862.3% | -4.0% | -4.1% |
| EBITDA | -219,739,176 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +212.6% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |